Maze Therapeutics, Inc. Common Stock

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026